A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

Lipoprotein(a) is believed to be a major carrier of oxidized phospholipids ... forming plaques that are similar to low-density lipoprotein (LDL), a known risk factor for cardiovascular events.